1. Novel Therapeutics in MS

3. Role of T Cells in MS

4. Role of B Cells in MS

5. Role of T Cells and B Cells in Disease Progression

6. T-Cell and B-Cell Targeted Therapies

7. T-Cell and B-Cell Targeted Therapies (cont)

8. Natalizumab: MOA

9. Natalizumab: Clinical Outcomes

10. Altering the Immune Function of T Cells and B Cells

11. Fingolimod: MOA

12. Fingolimod: Clinical Outcomes

13. Alemtuzumab: MOA

14. Alemtuzumab: Clinical Outcomes

15. Cladribine: MOA

16. Cladribine: Clinical Outcomes

17. Daclizumab: MOA

18. Daclizumab: Clinical Outcomes

19. Investigational T-Cell Targeting Therapies: Siponimod

20. S1PR Modulators

21. Investigational T-Cell Targeting Therapies: Other

22. B-Cell Ontogeny

23. Ocrelizumab: ORATORIO Study in PPMS

24. Immune-Depleting Strategies

25. Investigational B-Cell Targeted Therapies: Ofatumumab

26. Investigational B-Cell Targeted Therapies: Ofatumumab (cont)

27. Investigational B-Cell Targeted Therapies: Ublituximab and Inebilizumab

28. Looking to the Future

29. Conclusions

30. Abbreviations

31. Abbreviations (cont)

32. Abbreviations (cont)

33. Abbreviations (cont)